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  The clinical effect of Estracyt on untreated prostatlc carcinoma was evaluated． The subjects
consisted of 51 of 71 patients with prostatic carcinoma who were observed for 6 months or more
after oral administration of 560 mg of estramustine phosphate． This drug was effective in all pa－
tients： markedly effective in 34 （66．6％）， moderately effective in 13 （25．5％）， and slightly effective
in 4 （7，8906）． During the ’observation period varying from 6 months to 2 years and 6 months， 7
patients had recurrence of progression． The interval between the drug administration and recurrence
of progression varied from 6 months亡。 l year and lO months（mean，15．8 months）． Pros亡ate acid
phosphatase and r－semlnoprotein remained normal between 3 and 15 months after the administra－
tion but became elevated due to recurrence of progression after 18 months or more in some patientg． ．
92 泌尿系己要  37巻   1号  1991年
Blood testosterone， luteinizing hormone， and follicle stimulating hormone decreased while blood
cortisol increased． Therefore， estrogen was acting eflfectively． Side effects were observed in 56．9％
of the patients， the most frequent being mazoplasia in 33 patients （45．8％）， and cardiovascular
complications and． apoplexy in I I patients （15．3％）． Estracyt was effective for untreated prostatic
carclnoma but the problems such as recurrence of progression and side effects require further
examination．
                               （Acta Urol． Jpn． 37： 91－97， 1991）










































































Taale 1． Overall clinical effectiveness of Estracyt
  効果    著 効層群 効やや有効無効合計評価不能総合計
転移（一） 24 6 3 O 33 12（72．7） （18．2） （9．1） （10e．e） 45
転移（＋） 10 7 1 O 18 9（55 6） （3S．9） （5．5） （100．0） 27
fwa評価（，1（；r（，llll♂δ0（1認。）2172
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Table 3．Clinical effectiveness of Estracyt by
grade category．
  効果

























   34計   （66．6）




Table 2． Clinical effectiveness of Estracyt by
     stage category．
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Fig． 1． Effects of Estracyt on plasma levels




















































  貢投1M 3M  6M  gM  12M 15M 18M 21M 24M
  ち与
  著前
Fig． 2． Effects of Estracyt on plasma levels
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Fig． 3． Effects of Estracyt on plasma leveis
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Fig． 4． Effects of Estracyt on plasma levels
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Fig． 5． Effects of Estracyt on plasma levels
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